Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease

被引：0
|
作者：
Yacoub, W. [1 ]
Williet, N. [2 ]
Pouillon, L. [1 ,3 ]
Di-Bernado, T. [2 ]
Bittencourt, M. De Carvalho [4 ]
Nancey, S. [5 ]
Lopez, A. [1 ]
Paul, S. [6 ]
Zallot, C. [1 ]
Roblin, X. [2 ]
Peyrin-Biroulet, L. [1 ]
机构：
[1] Nancy Univ Hosp, Dept Gastroenterol, Vandoeuvre Les Nancy, France
[2] St Etienne Univ Hosp, Dept Gastroenterol, St Etienne, France
[3] Imelda GI Clin Res Ctr, Dept Gastroenterol, Bonheiden, Belgium
[4] Nancy Univ Hosp, Dept Immunol, Nancy, France
[5] Lyon Sud Hosp, Dept Gastroenterol, Pierre Benite, France
[6] St Etienne Univ Hosp, Dept Immunol, St Etienne, France
来源：
JOURNAL OF CROHNS & COLITIS | 2018年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P454
引用
收藏
页码：S334 / S334
页数：1
相关论文
共 50 条
  • [31] vedolizumab trough levels at week 6 and 14 correlate with clinical remission in inflammatory bowel disease patients
    Marino, M.
    Domenis, R.
    Biribin, L.
    Cifu, A.
    Navarria, L.
    Scardino, G.
    Fabris, M.
    [J]. JOURNAL OF CROHNS & COLITIS, 2020, 14 : S492 - S492
  • [32] Vedolizumab Trough Levels in Children With Anti-Tumor Necrosis Factor Refractory Inflammatory Bowel Disease
    Aardoom, Martine A.
    Jongsma, Maria M. E.
    de Vries, Annick
    Wolthoorn, Jasja
    de Ridder, Lissy
    Escher, Johanna C.
    [J]. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2020, 71 (04): : 501 - 507
  • [33] USTEKINUMAB TROUGH LEVELS ARE ASSOCIATED WITH SONOGRAPHIC TRANSMURAL HEALING IN PEDIATRIC INFLAMMATORY BOWEL DISEASE
    Kellar, Amelia
    Aronskyy, Illya
    Dubinsky, Marla C.
    Dolinger, Michael T.
    [J]. GASTROENTEROLOGY, 2023, 164 (06) : S1180 - S1180
  • [34] Ustekinumab trough levels are associated with sonographic transmural healing in Pediatric Inflammatory Bowel Disease
    Kellar, A.
    Aronskyy, I.
    Dubinsky, M. C.
    Dolinger, M. T.
    [J]. JOURNAL OF CROHNS & COLITIS, 2023, 17 : 515 - 517
  • [35] Preoperative serum vedolizumab levels do not predict postoperative outcomes in inflammatory bowel disease (IBD)
    Lopez, N.
    Zaghiyan, K.
    Melmed, G.
    McGovern, D.
    Jain, A.
    Targan, S.
    Fleshner, P.
    Landers, C.
    [J]. JOURNAL OF CROHNS & COLITIS, 2018, 12 : S303 - S304
  • [36] Vedolizumab Serum Trough Concentrations and Response to Dose Escalation in Inflammatory Bowel Disease
    Vaughn, Byron P.
    Yarur, Andres J.
    Graziano, Elliot
    Campbell, James P.
    Bhattacharya, Abhik
    Lee, Jennifer Y.
    Gheysens, Katherine
    Papamichael, Konstantinos
    Osterman, Mark T.
    Cheifetz, Adam S.
    Cross, Raymond K.
    [J]. JOURNAL OF CLINICAL MEDICINE, 2020, 9 (10) : 1 - 11
  • [37] Vedolizumab trough concentrations are associated with endoscopic response in patients with inflammatory bowel disease
    Chao, C. -Y.
    Restellini, S.
    Lemieux, C.
    Germain, P.
    Bitton, A.
    Lakatos, P. L.
    Wild, G.
    Seidman, E.
    Bessissow, T.
    Afif, W.
    [J]. JOURNAL OF CROHNS & COLITIS, 2018, 12 : S367 - S368
  • [38] Higher Vedolizumab Trough Levels Associated with Remission in Inflammatory Bowel Disease (IBD) Patients During Maintenance Therapy
    Ungaro, Ryan
    Jossen, Jacqueline
    Phan, Becky
    Chefitz, Ezra
    Jain, Anjali
    Naik, Snehal
    Dubinsky, Marla
    [J]. INFLAMMATORY BOWEL DISEASES, 2017, 23 : S7 - S7
  • [39] Association between infliximab trough levels, clinical remission, mucosal healing and quality of life in patients with inflammatory bowel disease on maintenance therapy
    Parra, R. S.
    Feitosa, M. R.
    Feres, O.
    Rocha, J. J. R. D.
    [J]. JOURNAL OF CROHNS & COLITIS, 2017, 11 : S292 - S292
  • [40] Association of trough vedolizumab levels with clinical, biological and endoscopic outcomes during maintenance therapy in inflammatory bowel disease
    Plevris, Nikolas
    Jenkinson, Philip W.
    Chuah, Cher S.
    Lyons, Mathew
    Merchant, Lynne M.
    Pattenden, Rebecca J.
    Arnott, Ian D.
    Jones, Gareth R.
    Lees, Charlie W.
    [J]. FRONTLINE GASTROENTEROLOGY, 2020, 11 (02) : 117 - 123
12345